U.S. Stem Cell Financials

$3.1 M

Revenue FY, 2016

$9.7 M

Mkt cap, 31-Oct-2017
Revenue growth (FY, 2015 - FY, 2016), %41%
Gross profit (FY, 2016)2.1 M
Gross profit margin (FY, 2016), %68%
Net income (FY, 2016)(2.1 M)
EBIT (FY, 2016)(1.2 M)
Closing share price, 31-Oct-20170
Cash, 31-Dec-201558.4 K

Financials

Market Value

Revenue/Financials

Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

96.1 k2.1 m2.2 m3.1 m

Revenue growth, %

2040%7%41%

Cost of goods sold

30.8 k844.9 k973 k972 k

Gross profit

65.3 k1.2 m1.2 m2.1 m

Gross profit Margin, %

68%59%56%68%

R&D expense

627 k66.4 k10 k919

Operating expense total

627 k66.4 k10 k919

EBIT

(2.8 m)(3.5 m)(2.6 m)(1.2 m)

EBIT margin, %

(2947%)(172%)(119%)(38%)

Interest expense

1.4 m1.6 m1.7 m1.2 m

Pre tax profit

(3.1 m)(2.3 m)(1.6 m)(2.1 m)

Net Income

(3.1 m)(2.3 m)(1.6 m)(2.1 m)

Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015

Cash

46.2 k36.7 k58.4 k

Current Assets

66.9 k141.3 k115.6 k

PP&E

9.1 k12.7 k14.2 k

Total Assets

86.1 k204.8 k229.1 k

Current Liabilities

13.4 m11.1 m5.7 m

Additional Paid-in Capital

103.8 m108.9 m114.6 m

Retained Earnings

(120.4 m)(122.1 m)

Total Equity

(13.7 m)(10.9 m)(7.7 m)

Financial Leverage

0 x0 x0 x

Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(3.1 m)(2.3 m)(1.6 m)(2.1 m)

Depreciation and Amortization

2.2 k4.5 k5.3 k5.8 k

Cash From Operating Activities

(1.9 m)(1.1 m)(844.7 k)

Cash From Investing Activities

(9.4 k)(57.8 k)(234 k)

Interest Paid

521.7 k429.6 k321.8 k

Ratios

USDY, 2016

Revenue/Employee

1 m